Loading
A phase 3 trial of Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06128837 by Luye Pharma Group Ltd., with 686 participants planned, started 2024-03-03 and due to reach its primary completion in 2028-06. Interventions recorded: Irinotecan hydrochloride liposome Injection, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Luye Pharma Group, Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Luye Pharma Group, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/